Table 1 Characteristics of patients in the present study [n(%)]
From: ADP-dependent glucokinase controls metabolic fitness in prostate cancer progression
Variables | Total (n = 45) | ADPGK low expression (n = 19, 42.2%) | ADPGK high expression (n = 26, 57.8%) | P |
|---|---|---|---|---|
Age (years) | 0.206 | |||
  < 70 | 14 (31.1) | 8 (42.1) | 6 (23.1) |  |
  ≥ 70 | 31 (68.9) | 11 (57.9) | 20 (76.9) |  |
BMI (kg/m2) | 1.000 | |||
  < 25 | 30 (66.7) | 13 (68.4) | 17 (65.4) |  |
  ≥  25 | 15 (33.3) | 6 (31.6) | 9 (34.6) |  |
Baseline PSA (ng/ml) | 0.764 | |||
  < 20 | 21 (46.7) | 8 (42.1) | 13 (50.0) |  |
  ≥ 20 | 24 (53.3) | 11 (57.9) | 13 (50.0) |  |
Neoadjuvant ADT | 0.024 | |||
 No | 32 (71.1) | 17 (89.5) | 15 (57.7) |  |
 Yes | 13 (28.9) | 2 (10.5) | 11 (42.3) |  |
pT stage | 1.000 | |||
  < pT3 | 21 (46.7) | 9 (47.4) | 12 (46.2) |  |
  ≥  pT3 | 24 (53.3) | 10 (52.6) | 14 (53.8) |  |
GS | 0.371 | |||
  < 8 | 27 (60.0) | 13 (68.4) | 14 (53.8) |  |
  ≥ 8 | 18 (40.0) | 6 (31.6) | 12 (46.2) |  |
EPE | 1.000 | |||
 − | 21 (46.7) | 9 (47.4) | 12 (46.2) |  |
  +  | 24 (53.3) | 10 (52.6) | 14 (53.8) |  |
SVI | 0.507 | |||
 − | 32 (71.1) | 15 (78.9) | 17 (65.4) |  |
  +  | 13 (28.9) | 4 (21.1) | 9 (34.6) |  |
PNI | 0.341 | |||
 − | 13 (28.9) | 7 (36.8) | 6 (23.1) |  |
  +  | 32 (71.1) | 12 (63.2) | 20 (76.9) |  |
PSM | 0.734 | |||
 − | 12 (26.7) | 6 (31.6) | 6 (23.1) |  |
  +  | 33 (73.3) | 13 (68.4) | 20 (76.9) |  |
ADT | 0.770 | |||
 No | 20 (44.4) | 9 (47.4) | 11 (42.3) |  |
 Yes | 25 (55.6) | 10 (52.6) | 15 (57.7) |  |
Adjuvant radiotherapy | 0.371 | |||
 No | 27 (60.0) | 13 (68.4) | 14 (53.8) |  |
 Yes | 18 (40.0) | 6 (31.6) | 12 (46.2) |  |
Post RARP 3-month-PSA (ng/ml) | 0.764 | |||
  < 0.003 | 10 (22.2) | 5 (26.3) | 5 (19.2) |  |
 0.003–0.200 | 26 (57.8) | 11 (57.9) | 15 (57.7) |  |
  > 0.200 | 9 (20.0) | 3 (15.8) | 6 (23.1) |  |